24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
TROMLIEVA 50MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | TROMLIEVA 50MG |
|---|---|
| Composition | Eltrombopag Olamine Tablets 50mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | Strip (4 x 7) |
| Country of Origin | India |
TROMLIEVA 50MG (Eltrombopag Olamine Tablets 50mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
TROMLIEVA 50 MG (Eltrombopag Olamine Tablets 50 mg) is a prescription medicine containing Eltrombopag Olamine 50 mg, a thrombopoietin receptor agonist used to increase platelet production in patients with certain blood disorders. It is commonly prescribed for individuals with chronic immune thrombocytopenia (ITP), severe aplastic anemia, and thrombocytopenia associated with chronic hepatitis C under the supervision of a qualified healthcare professional.
Platelets are blood cells that play a vital role in blood clotting and preventing excessive bleeding. When platelet levels become too low, patients may experience symptoms such as easy bruising, prolonged bleeding, frequent nosebleeds, bleeding gums, or tiny red spots on the skin known as petechiae. TROMLIEVA 50 MG helps address this problem by stimulating the body’s natural platelet production process.
Eltrombopag works by activating thrombopoietin receptors located in the bone marrow. These receptors are responsible for signaling the production of platelets. By stimulating these receptors, TROMLIEVA 50 MG helps increase platelet counts and reduce the risk of bleeding complications.
Unlike platelet transfusions, which provide a temporary increase in platelet levels, Eltrombopag encourages the body to produce its own platelets, making it a valuable option for long-term management in eligible patients.
TROMLIEVA 50 MG is commonly prescribed for:
The medicine is often recommended when other treatments have not provided adequate platelet improvement or when long-term platelet support is required.
Manufactured according to stringent pharmaceutical quality standards, TROMLIEVA 50 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Eltrombopag therapy typically require routine blood tests, platelet count monitoring, liver function assessments, and regular medical evaluations to ensure safe and effective treatment.
Due to its proven ability to increase platelet production, TROMLIEVA 50 MG has become an important treatment option in modern hematology care.
TROMLIEVA 50 MG (Eltrombopag Olamine Tablets 50 mg) is primarily used to increase platelet counts in patients with specific blood disorders.
The medicine is widely used in patients with chronic ITP who have low platelet counts and an increased risk of bleeding.
Eltrombopag may help improve blood cell production in eligible patients with severe aplastic anemia.
The medicine may be prescribed for patients with low platelet counts associated with chronic hepatitis C infection.
Doctors may recommend Eltrombopag in selected bone marrow failure conditions.
The medicine helps maintain safer platelet levels in eligible patients.
It supports ongoing treatment plans for chronic platelet disorders.
Eltrombopag plays an important role in specialized blood disorder treatment protocols.
Eltrombopag belongs to a class of medicines known as Thrombopoietin Receptor Agonists.
TROMLIEVA works by:
This targeted mechanism helps improve platelet production naturally within the body.
Like all medicines, TROMLIEVA 50 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Headaches are among the most frequently reported side effects.
Some patients may experience mild nausea during treatment.
Weakness and tiredness may occur.
Muscle aches and discomfort may develop.
Some individuals may experience joint-related discomfort.
Digestive disturbances may occasionally occur.
Cold-like symptoms may develop in some patients.
Reduced appetite may affect nutritional intake.
Liver-related changes may require monitoring during treatment.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of TROMLIEVA 50 MG (Eltrombopag Olamine Tablets 50 mg) should always be determined by a qualified healthcare professional.
The dosage varies according to the specific blood disorder being treated.
Regular platelet monitoring helps guide treatment decisions.
Patients with liver conditions may require dosage adjustments.
Doctors may modify therapy based on platelet count improvements.
Age, health status, and concurrent treatments may influence dosage recommendations.
Before starting treatment, inform your doctor if you have:
Patients should also disclose all prescription medications, supplements, vitamins, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant and breastfeeding women should use this medicine only if specifically recommended by a healthcare professional.
It is used to increase platelet counts in patients with chronic immune thrombocytopenia, severe aplastic anemia, and certain cases of hepatitis C-associated thrombocytopenia.
Eltrombopag Olamine is a thrombopoietin receptor agonist that stimulates platelet production in the bone marrow.
It activates thrombopoietin receptors, encouraging the bone marrow to produce more platelets.
No. It is not a steroid. It works through a different mechanism that stimulates platelet production.
Yes. By increasing platelet counts, it may help lower the risk of bleeding complications in eligible patients.
Yes. Routine platelet counts and liver function tests are important during treatment.
Treatment duration depends on the patient's condition, treatment response, and healthcare provider's recommendations.
Yes. This medicine should only be used under the supervision of qualified healthcare professionals experienced in hematology and blood disorder management.